LncRNAs LY86-AS1 and VIM-AS1 Distinguish Plasma Cell Leukemia
Patients from Multiple Myeloma Patients

J 2021

LncRNAs LY86-AS1 and VIM-AS1 Distinguish Plasma Cell Leukemia Patients from Multiple Myeloma Patients

BÚTOVÁ, Romana, Petra VYCHYTILOVÁ, Jana GREGOROVÁ, Lenka RADOVÁ, Martina ALMASI et. al.

Základní údaje

Originální název

LncRNAs LY86-AS1 and VIM-AS1 Distinguish Plasma Cell Leukemia Patients from Multiple Myeloma Patients

Autoři

BÚTOVÁ, Romana (703 Slovensko, domácí), Petra VYCHYTILOVÁ (203 Česká republika, domácí), Jana GREGOROVÁ (203 Česká republika, domácí), Lenka RADOVÁ (203 Česká republika, domácí), Martina ALMASI (203 Česká republika), Renata BEZDEKOVA (203 Česká republika), Lucie BROŽOVÁ (203 Česká republika, domácí), Jiří JARKOVSKÝ (203 Česká republika, domácí), Zdenka KNECHTOVA (203 Česká republika), Martin ŠTORK (203 Česká republika), Luděk POUR (203 Česká republika) a Sabina ŠEVČÍKOVÁ (203 Česká republika, garant, domácí)

Vydání

Biomedicines, Basel, MDPI, 2021, 2227-9059

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30104 Pharmacology and pharmacy

Stát vydavatele

Švýcarsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 4.757

Kód RIV

RIV/00216224:14110/21:00123611

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.3390/biomedicines9111637

UT WoS

000725844800001

Klíčová slova anglicky

multiple myeloma; plasma cell leukemia; long non-coding RNA; next-generation sequencing; biomarkers; disease progression

Štítky

14110518, 14119612, podil, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 11. 1. 2022 07:19, Mgr. Tereza Miškechová

Anotace

V originále

Long non-coding RNAs (lncRNAs) are functional RNAs longer than 200 nucleotides. Due to modern genomic techniques, the involvement of lncRNAs in tumorigenesis has been revealed; however, information concerning lncRNA interplay in multiple myeloma (MM) and plasma cell leukemia (PCL) is virtually absent. Herein, we aimed to identify the lncRNAs involved in MM to PCL progression. We investigated representative datasets of MM and PCL patients using next-generation sequencing. In total, 13 deregulated lncRNAs (p < 0.00025) were identified; four of them were chosen for further validation in an independent set of MM and PCL patients by RT-qPCR. The obtained results proved the significant downregulation of lymphocyte antigen antisense RNA 1 (LY86-AS1) and VIM antisense RNA 1 (VIM-AS1) in PCL compared to MM. Importantly, these two lncRNAs could be involved in the progression of MM into PCL; thus, they could serve as promising novel biomarkers of MM progression.

Návaznosti

MUNI/A/1698/2020, interní kód MU

Název: Od molekulární, buněčné a tkáňové k systémové patofyziologii vybraných komplexních nemocí (Akronym: ComplexPF)

Investor: Masarykova univerzita, Od molekulární, buněčné a tkáňové k systémové patofyziologii vybraných komplexních nemocí

Citovat

BÚTOVÁ, Romana, Petra VYCHYTILOVÁ, Jana GREGOROVÁ, Lenka RADOVÁ, Martina ALMASI, Renata BEZDEKOVA, Lucie BROŽOVÁ, Jiří JARKOVSKÝ, Zdenka KNECHTOVA, Martin ŠTORK, Luděk POUR a Sabina ŠEVČÍKOVÁ. LncRNAs LY86-AS1 and VIM-AS1 Distinguish Plasma Cell Leukemia Patients from Multiple Myeloma Patients. Biomedicines. Basel: MDPI, 2021, roč. 9, č. 11, s. 1-11. ISSN 2227-9059. Dostupné z: https://dx.doi.org/10.3390/biomedicines9111637.

@article{1818659,
   author = {Bútová, Romana and Vychytilová, Petra and Gregorová, Jana and Radová, Lenka and Almasi, Martina and Bezdekova, Renata and Brožová, Lucie and Jarkovský, Jiří and Knechtova, Zdenka and Štork, Martin and Pour, Luděk and Ševčíková, Sabina},
   article_location = {Basel},
   article_number = {11},
   doi = {http://dx.doi.org/10.3390/biomedicines9111637},
   keywords = {multiple myeloma; plasma cell leukemia; long non-coding RNA; next-generation sequencing; biomarkers; disease progression},
   language = {eng},
   issn = {2227-9059},
   journal = {Biomedicines},
   title = {LncRNAs LY86-AS1 and VIM-AS1 Distinguish Plasma Cell Leukemia Patients from Multiple Myeloma Patients},
   url = {https://www.mdpi.com/2227-9059/9/11/1637},
   volume = {9},
   year = {2021}
}

TY  - JOUR
ID  - 1818659
AU  - Bútová, Romana - Vychytilová, Petra - Gregorová, Jana - Radová, Lenka - Almasi, Martina - Bezdekova, Renata - Brožová, Lucie - Jarkovský, Jiří - Knechtova, Zdenka - Štork, Martin - Pour, Luděk - Ševčíková, Sabina
PY  - 2021
TI  - LncRNAs LY86-AS1 and VIM-AS1 Distinguish Plasma Cell Leukemia Patients from Multiple Myeloma Patients
JF  - Biomedicines
VL  - 9
IS  - 11
SP  - 1-11
EP  - 1-11
PB  - MDPI
SN  - 22279059
KW  - multiple myeloma
KW  - plasma cell leukemia
KW  - long non-coding RNA
KW  - next-generation sequencing
KW  - biomarkers
KW  - disease progression
UR  - https://www.mdpi.com/2227-9059/9/11/1637
N2  - Long non-coding RNAs (lncRNAs) are functional RNAs longer than 200 nucleotides. Due to modern genomic techniques, the involvement of lncRNAs in tumorigenesis has been revealed; however, information concerning lncRNA interplay in multiple myeloma (MM) and plasma cell leukemia (PCL) is virtually absent. Herein, we aimed to identify the lncRNAs involved in MM to PCL progression. We investigated representative datasets of MM and PCL patients using next-generation sequencing. In total, 13 deregulated lncRNAs (p < 0.00025) were identified; four of them were chosen for further validation in an independent set of MM and PCL patients by RT-qPCR. The obtained results proved the significant downregulation of lymphocyte antigen antisense RNA 1 (LY86-AS1) and VIM antisense RNA 1 (VIM-AS1) in PCL compared to MM. Importantly, these two lncRNAs could be involved in the progression of MM into PCL; thus, they could serve as promising novel biomarkers of MM progression.
ER  -

BÚTOVÁ, Romana, Petra VYCHYTILOVÁ, Jana GREGOROVÁ, Lenka RADOVÁ, Martina ALMASI, Renata BEZDEKOVA, Lucie BROŽOVÁ, Jiří JARKOVSKÝ, Zdenka KNECHTOVA, Martin ŠTORK, Luděk POUR a Sabina ŠEVČÍKOVÁ. LncRNAs LY86-AS1 and VIM-AS1 Distinguish Plasma Cell Leukemia Patients from Multiple Myeloma Patients. \textit{Biomedicines}. Basel: MDPI, 2021, roč.~9, č.~11, s.~1-11. ISSN~2227-9059. Dostupné z: https://dx.doi.org/10.3390/biomedicines9111637.

Podrobný výpis o publikaci